CorFlow Therapeutics AG announced that the company has completed the 2nd close of its Seed+ financing round.
To date and since the CorFlow foundation in 2016, the company has raised a total of USD 9.7M (CHF 9.4M) in seed funding.
The seed rounds have been funded by experienced private medical device investors who over the last decades have supported several breakthrough interventional cardiology technologies.
The milestones to be reached over the coming months will be the basis for raising the A round in 2019 securing the long-term R&D, clinical and regulatory activities of the company.
Bratschi advised CorFlow in this transaction with a team led by Harald Maag (picture), Ion Eglin and Christian Beutter.
Law Firms: Bratschi Wiederkehr & Buob Ltd.;
Clients: CorFlow Therapeutics Ltd.;